HUE053115T2 - Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére - Google Patents
Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezeléséreInfo
- Publication number
- HUE053115T2 HUE053115T2 HUE16805522A HUE16805522A HUE053115T2 HU E053115 T2 HUE053115 T2 HU E053115T2 HU E16805522 A HUE16805522 A HU E16805522A HU E16805522 A HUE16805522 A HU E16805522A HU E053115 T2 HUE053115 T2 HU E053115T2
- Authority
- HU
- Hungary
- Prior art keywords
- treatment
- pharmaceutical formulations
- inflammatory conditions
- topical pharmaceutical
- topical
- Prior art date
Links
- 230000004968 inflammatory condition Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260716P | 2015-11-30 | 2015-11-30 | |
| US201662420987P | 2016-11-11 | 2016-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE053115T2 true HUE053115T2 (hu) | 2021-06-28 |
Family
ID=57471943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16805522A HUE053115T2 (hu) | 2015-11-30 | 2016-11-23 | Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20170152273A1 (https=) |
| EP (2) | EP3383363B1 (https=) |
| JP (1) | JP6725403B2 (https=) |
| KR (1) | KR102106230B1 (https=) |
| CN (1) | CN108366958A (https=) |
| AU (1) | AU2016362668C1 (https=) |
| BR (1) | BR112018010464B1 (https=) |
| CA (1) | CA2949614C (https=) |
| CY (1) | CY1123845T1 (https=) |
| DK (1) | DK3383363T3 (https=) |
| ES (1) | ES2858311T3 (https=) |
| HK (1) | HK1257818A1 (https=) |
| HU (1) | HUE053115T2 (https=) |
| IL (1) | IL259693B2 (https=) |
| MX (1) | MX378145B (https=) |
| NZ (1) | NZ742208A (https=) |
| PL (1) | PL3383363T3 (https=) |
| PT (1) | PT3383363T (https=) |
| RU (1) | RU2724053C2 (https=) |
| SG (2) | SG10202112628UA (https=) |
| SI (1) | SI3383363T1 (https=) |
| TW (1) | TWI627974B (https=) |
| WO (1) | WO2017093857A1 (https=) |
| ZA (1) | ZA201802920B (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
| ES2824552T3 (es) | 2015-03-04 | 2021-05-12 | Vanda Pharmaceuticals Inc | Método de tratamiento con tradipitant |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SG10201913990RA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US20210228575A1 (en) * | 2019-09-30 | 2021-07-29 | Abbvie Inc. | Treating spondyloarthritic and psoriatic conditions with upadacitinib |
| US11447506B2 (en) | 2016-05-09 | 2022-09-20 | Anacor Pharmaceuticals, Inc. | Crystal forms of crisaborole in free form and preparation method and use thereof |
| WO2017193914A1 (zh) * | 2016-05-09 | 2017-11-16 | 苏州科睿思制药有限公司 | 克立硼罗游离形式的晶型及其制备方法和用途 |
| WO2017203514A1 (en) * | 2016-05-26 | 2017-11-30 | Perrigo Api Ltd | Polymorphs of crisaborole and production processes therefor |
| GB201701583D0 (en) | 2017-01-31 | 2017-03-15 | Drug Delivery Solutions Ltd | Topical composition |
| WO2018224923A1 (en) * | 2017-06-05 | 2018-12-13 | Glenmark Pharmaceuticals Limited | Process for preparation of crisaborole |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US20200155524A1 (en) * | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US11534493B2 (en) | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| US10329311B1 (en) | 2017-12-21 | 2019-06-25 | Olon S.P.A. | Process for the preparation of crisaborole |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CN109985000B (zh) * | 2017-12-29 | 2022-09-02 | 苏州旺山旺水生物医药有限公司 | 克立硼罗微乳组合物 |
| PL3737685T3 (pl) * | 2018-01-09 | 2023-10-02 | Halcyon Labs Private Limited | Sposób wytwarzania kryzaborolu i jego związków pośrednich |
| US10597410B2 (en) | 2018-02-02 | 2020-03-24 | Dipharma Francis S.R.L. | Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent |
| JP7777921B2 (ja) * | 2018-02-09 | 2025-12-01 | ガルデルマ ホールディング エスエー | 中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ |
| EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
| CN108210462A (zh) * | 2018-03-29 | 2018-06-29 | 苏州尚宜佳生物科技有限公司 | 一种克立硼罗局部缓释脂质体的制法与应用 |
| CN108324724A (zh) * | 2018-04-10 | 2018-07-27 | 苏州芝宇生物科技有限公司 | 一种克立硼罗可溶性膜制剂的制法及其应用 |
| CN110464702A (zh) * | 2018-05-09 | 2019-11-19 | 上海键合医药科技有限公司 | 一种克立硼罗的软膏剂及其制备方法 |
| EP3801461A2 (en) | 2018-06-04 | 2021-04-14 | Arcutis, Inc. | Method and formulation for improving roflumilast skin penetration lag time |
| CN108992454B (zh) | 2018-06-20 | 2020-06-02 | 合肥医工医药股份有限公司 | 一种治疗皮肤炎症性疾病的复方药物组合物 |
| CN108785379A (zh) * | 2018-06-26 | 2018-11-13 | 苏州尚宜佳生物科技有限公司 | 一种克立硼罗清凉缓释膜及其制备方法 |
| CN108524648A (zh) * | 2018-06-26 | 2018-09-14 | 苏州尚宜佳生物科技有限公司 | 一种克立硼罗复合保健缓释膜及其制备方法 |
| CN108938603A (zh) * | 2018-06-27 | 2018-12-07 | 苏州尚宜佳生物科技有限公司 | 一种缓释效果好的克立硼罗缓释膜及其制备方法 |
| CN108785372A (zh) * | 2018-06-27 | 2018-11-13 | 苏州尚宜佳生物科技有限公司 | 一种克立硼罗燥湿利尿缓释膜及其制备方法 |
| CN108926547A (zh) * | 2018-07-02 | 2018-12-04 | 苏州尚宜佳生物科技有限公司 | 一种粘贴效果好的克立硼罗缓释膜及其制备方法 |
| CN108938602A (zh) * | 2018-07-02 | 2018-12-07 | 苏州尚宜佳生物科技有限公司 | 一种吸收效果好的克立硼罗缓释膜及其制备方法 |
| CN108853063A (zh) * | 2018-07-04 | 2018-11-23 | 苏州尚宜佳生物科技有限公司 | 一种透气效果好的克立硼罗缓释膜的制备方法 |
| CN108853062A (zh) * | 2018-07-04 | 2018-11-23 | 苏州尚宜佳生物科技有限公司 | 一种肤感克立硼罗缓释膜的制备方法 |
| CN108853064A (zh) * | 2018-07-09 | 2018-11-23 | 苏州尚宜佳生物科技有限公司 | 一种防水透气克立硼罗缓释膜的制备方法 |
| CN108653246A (zh) * | 2018-07-09 | 2018-10-16 | 苏州尚宜佳生物科技有限公司 | 一种防水效果好的克立硼罗缓释膜的制备方法 |
| JP7268132B2 (ja) | 2018-07-31 | 2023-05-02 | エムシー２・セラピューティクス・リミテッド | 局所用組成物 |
| WO2020051230A1 (en) * | 2018-09-04 | 2020-03-12 | X-Rx, Inc. | Amorphous pharmaceutical compositions and uses thereof |
| CN112770756A (zh) * | 2018-09-29 | 2021-05-07 | 苏州科睿思制药有限公司 | 一种Upadacitinib的晶型及其制备方法和用途 |
| CN111217819B (zh) * | 2018-11-27 | 2021-05-14 | 杭州科巢生物科技有限公司 | 乌帕替尼的合成方法 |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| EP4140480A4 (en) * | 2020-04-23 | 2024-06-12 | Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. | DRUG COMBINATION AND USE |
| WO2021257914A1 (en) * | 2020-06-17 | 2021-12-23 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| JP2023538362A (ja) * | 2020-08-20 | 2023-09-07 | ファイザー・インク | １（ｒ）－４－（５－（４－メトキシ－３－プロポキシフェニル）ピリジン－３－イル）－１，２－オキサボロラン－２－オールの安定な局所製剤 |
| CN112168774A (zh) * | 2020-11-04 | 2021-01-05 | 南京康川济医药科技有限公司 | 一种巴瑞克替尼乳膏及其制备方法和应用 |
| US11707454B2 (en) | 2020-12-04 | 2023-07-25 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having antifungal properties |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| CN116867494A (zh) | 2021-02-15 | 2023-10-10 | 凯麦拉医疗公司 | Irak4降解剂和其用途 |
| CA3236265A1 (en) | 2021-10-29 | 2023-05-04 | William Leong | Irak4 degraders and synthesis thereof |
| CN118765194A (zh) | 2021-12-28 | 2024-10-11 | 阿尔库缇斯生物疗法股份有限公司 | 局部罗氟司特气溶胶泡沫 |
| CA3248817A1 (en) * | 2022-01-20 | 2023-07-27 | Renata Pharmaceutical (Ireland) Limited | Extended-release pharmaceutical composition of Upadacitinib |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| WO2024058848A1 (en) | 2022-09-15 | 2024-03-21 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
| CN115417890A (zh) * | 2022-09-24 | 2022-12-02 | 中山万远新药研发有限公司 | 克立硼罗的新晶型及其制备方法与用途 |
| CN116715687A (zh) * | 2023-05-25 | 2023-09-08 | 福建南方制药股份有限公司 | 一种工业化制备克立硼罗晶型i的方法 |
| CN119345120B (zh) * | 2024-12-26 | 2025-03-14 | 新基元(北京)医药科技有限公司 | 一种克立硼罗软膏及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282216A (en) * | 1977-04-20 | 1981-08-04 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
| EP2343304B1 (en) * | 2005-02-16 | 2015-06-10 | Anacor Pharmaceuticals, Inc. | Biocidal boronophthalide compounds |
| PT1988779E (pt) | 2006-02-16 | 2015-09-04 | Anacor Pharmaceuticals Inc | Moléculas pequenas contendo boro como agentes antiinflamatórios |
| JP5745279B2 (ja) * | 2008-01-09 | 2015-07-08 | アナコール ファーマシューティカルズ，インコーポレイテッド | 抗炎症剤としてのホウ素含有小分子 |
| WO2009111676A2 (en) | 2008-03-06 | 2009-09-11 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules as anti-inflammatory agents |
| KR20150065941A (ko) * | 2008-03-06 | 2015-06-15 | 아나코르 파마슈티칼스 인코포레이티드 | 소염제로써 붕소가 함유된 소분자 |
| WO2011094450A1 (en) | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
| GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
-
2016
- 2016-11-23 SG SG10202112628UA patent/SG10202112628UA/en unknown
- 2016-11-23 KR KR1020187018210A patent/KR102106230B1/ko active Active
- 2016-11-23 IL IL259693A patent/IL259693B2/en unknown
- 2016-11-23 RU RU2018119295A patent/RU2724053C2/ru active
- 2016-11-23 HU HUE16805522A patent/HUE053115T2/hu unknown
- 2016-11-23 PT PT168055226T patent/PT3383363T/pt unknown
- 2016-11-23 HK HK19100162.1A patent/HK1257818A1/zh unknown
- 2016-11-23 WO PCT/IB2016/057073 patent/WO2017093857A1/en not_active Ceased
- 2016-11-23 MX MX2018006578A patent/MX378145B/es unknown
- 2016-11-23 PL PL16805522T patent/PL3383363T3/pl unknown
- 2016-11-23 SI SI201631089T patent/SI3383363T1/sl unknown
- 2016-11-23 DK DK16805522.6T patent/DK3383363T3/da active
- 2016-11-23 ES ES16805522T patent/ES2858311T3/es active Active
- 2016-11-23 EP EP16805522.6A patent/EP3383363B1/en active Active
- 2016-11-23 SG SG11201803728YA patent/SG11201803728YA/en unknown
- 2016-11-23 BR BR112018010464-7A patent/BR112018010464B1/pt active IP Right Grant
- 2016-11-23 EP EP20215322.7A patent/EP3831389A1/en not_active Withdrawn
- 2016-11-23 NZ NZ742208A patent/NZ742208A/en unknown
- 2016-11-23 AU AU2016362668A patent/AU2016362668C1/en active Active
- 2016-11-23 CN CN201680069997.3A patent/CN108366958A/zh active Pending
- 2016-11-25 CA CA2949614A patent/CA2949614C/en active Active
- 2016-11-28 JP JP2016229721A patent/JP6725403B2/ja active Active
- 2016-11-29 TW TW105139318A patent/TWI627974B/zh active
- 2016-11-30 US US15/364,347 patent/US20170152273A1/en not_active Abandoned
-
2018
- 2018-05-04 ZA ZA2018/02920A patent/ZA201802920B/en unknown
-
2019
- 2019-06-25 US US16/451,107 patent/US20190308994A1/en not_active Abandoned
-
2021
- 2021-02-25 CY CY20211100160T patent/CY1123845T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE053115T2 (hu) | Topikális gyógyszerészeti formulációk gyulladással összefüggõ állapotok kezelésére | |
| PT3297605T (pt) | Composições farmacêuticas tópicas | |
| DK3269716T3 (da) | Hidtil ukendte forbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske lidelser | |
| DK3102213T3 (da) | Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser | |
| DK3256138T3 (da) | Farmaceutiske sammensætninger omfattende meloxicam | |
| PT4070788T (pt) | Formulações farmacêuticas | |
| HUE058713T2 (hu) | Kinolin-származékok gyulladásos megbetegedések kezelésére | |
| DK3253382T3 (da) | Farmaceutiske sammensætninger til kombinationsterapi | |
| BR112016021012A2 (pt) | composições farmacêuticas de compostos terapeuticamente ativos. | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| EP3328353A4 (en) | TOPICAL SKIN FORMULATIONS | |
| HUE037179T2 (hu) | Gyógyászati kompozíciók izom-rendellenességek kezelésére | |
| EP3383912A4 (en) | TOPICAL FORMULATIONS | |
| DK3397619T3 (da) | Salve | |
| HUE054735T2 (hu) | Topikális formuláció | |
| DK2886108T4 (da) | Optimeret farmaceutisk formulering til behandling af inflammatoriske ændringer af øsofagus | |
| DK3280447T3 (da) | Farmaceutiske formuleringer | |
| EP3328354A4 (en) | TOPICAL SKIN FORMULATIONS | |
| EP3337463A4 (en) | PHARMACEUTICAL FORMULATIONS | |
| IL256919A (en) | Pharmaceutical compositions useful for the treatment of tissue injury | |
| KR101583452B9 (ko) | 위장질환 치료용 의약 조성물 | |
| ZA201707777B (en) | Pharmaceutical formulation for the treatment of inflammatory changes to the rectum | |
| TR201512960A1 (tr) | Topi̇kal formülasyonlar | |
| MA42111A (fr) | Compositions pharmaceutiques topiques | |
| BR112016021232A2 (pt) | composições farmacêuticas de compostos terapeuticamente ativos |